Guggenheim has initiated coverage on Adaptive Biotechnologies Corp (ADPT) with a Buy rating, marking the firm’s first assessment of the company’s investment potential. This decision, made on September 29, 2025, comes as Adaptive Biotechnologies continues to develop its immune medicine platform, which aims to transform disease diagnosis and treatment.
Headquartered in Seattle, Washington, Adaptive Biotechnologies operates within the Life Sciences Tools & Services industry. The company harnesses the biology of the adaptive immune system, offering insights that drive drug development and clinical diagnostics. Its two main business segments, Minimal Residual Disease (MRD) and Immune Medicine (IM), focus on advancing therapies for cancer and autoimmune diseases.
As of now, ADPT shares are trading at $17.56, and the company boasts a market cap of $2.5 billion. Analysts have shown a generally positive outlook, with a consensus rating of Buy based on 5 Strong Buy, 7 Buy, and 2 Hold ratings as of November 1, 2025.
Upcoming earnings reports are anticipated, with estimates for Q2 2026 at an EPS of $-0.17 and revenue of $60.6 million, and Q3 2026 expected to show an EPS of $-0.15 with revenue of $67.1 million.
Analyst ratings and price targets provide insights based on financial models and research. However, they reflect assumptions that may not always come to fruition. Investors should consider a range of factors, including company fundamentals and market trends, when making decisions. Analyst opinions can evolve as new information becomes available, highlighting the importance of staying informed.